

Factors	Relative Risk	95% CI	P
AML			
*URD vs. ^a Sib (no acute GVHD)	2.76	2.05-3.72	<0.0001
*URD vs. ^a Sib (acute GVHD present)	1.19	0.85-1.66	0.32
Chronic GVHD	1.49	1.14-1.95	0.004
Interaction present between donor source and acute GVHD. Model also adjusted for disease stage, donor age, GVHD prophylaxis, karnofsky score and stratified by graft type and gender mismatch.			
ALL			
URD vs. ^a Sib	1.19	0.88-1.60	0.25
cGVHD	1.79	1.21-2.63	0.0033
Acute GVHD (interaction with disease stage and patient age)			
No acute GVHD			
^b Disease Stage			
^a Early	1.0		
Intermediate	2.11	1.34-3.32	0.0014
Advanced	3.12	2.00-4.86	<0.0001
Patient age			
^a 18-30	1.0		
31-40	2.54	1.59-4.05	<0.0001
41-50	1.93	1.14-3.26	0.014
51-60	2.43	1.31-4.50	0.0048
Acute GVHD Present			
^b Disease stage			
^a Early	1.0		
Intermediate	0.98	0.61-1.56	0.92
Advanced	1.11	0.67-1.84	0.69
Patient age			
^a 18-30	1.0		
31-40	0.78	0.47-1.30	0.34
41-50	1.62	0.99-2.65	0.057
51-60	1.91	0.95-3.84	0.069
Interaction present between aGVHD with patient age and disease stage. Model stratified by graft type and gender mismatch.			
CML			
URD vs. Sib	1.02	0.83-1.25	0.85
Acute GVHD	2.59	2.16-3.11	<0.0001
Chronic GVHD	1.61	1.28-2.04	<0.0001
Model also adjusted for patient age, time from diagnosis to transplant and disease stage and stratified by graft type and gender mismatch.			

Abbreviations: URD = unrelated donor; Sib = HLA-identical sibling; AML = acute myeloid leukemia; ALL = acute lymphoid leukemia; CML = chronic myeloid leukemia, GVHD = graft-versus-host disease; CI = confidence interval. ^a Reference group; ^b Disease status is categorized as follows: Early - includes AML and ALL in CR1 or CML in first chronic phase; Intermediate - includes AML and ALL in \geq CR2 or CML in AP or \geq second chronic phase. Advanced - includes AML and ALL with relapse or primary induction failure or CML in blast crisis.